Loud Echo Launches First Real-Time Generative Advertising Platform
For decades, ad-tech optimized who to target and where to show ads, while creative remained static. Unlike traditional DSPs, Loud Echo integrates real-time creative generation, targeting and bidding into one system. Now ads can adapt to every audience, context, and placement on the fly. Campaigns improve with every impression, eliminating ad fatigue and increasing brand memorability.
"Programmatic has always been real-time," said
Loud Echo connects directly to existing programmatic exchanges, supporting display ads across major publishers and apps. It ingests brand guidelines, do's and don'ts and tone of voice, embedding them into a low-latency generative AI stack.
"This is a genuine revolution in communications," said
The platform is live and running campaigns with large companies across a variety of sectors – e-commerce, gaming, finance and more. Loud Echo's contextual creative have shown 3X higher performance than static ads.
The team is led by top experts in communications, AI, and ad-tech, with decades of experience building deep learning systems. COO
About Loud Echo
Loud Echo is built by Teza, a technology company building the future of AI-driven communications. They are backed by 8VC, Pitango,
Launch video: https://x.com/danieljkeyes/status/1981034597379940725?s=46&t=7YTUdL_LSjcbHhCB8yd0Ig
Follow us on X: @loudecho_ai
Sign up for early access here.
We're Hiring
Loud Echo is recruiting engineers and AI researchers to build the next generation of creative infrastructure—systems that generate, decide, and evolve in real-time. Learn more at loudecho.ai or contact [email protected].
Photo: https://mma.prnewswire.com/media/2835501/Loud_Echo_1.jpg
Photo: https://mma.prnewswire.com/media/2835500/Loud_Echo_2.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/loud-echo-launches-first-real-time-generative-advertising-platform-302629394.html
SOURCE Loud Echo
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- PureHealth Research Utilizes Bioavailable Cranberry and Astragalus in Premium Natural Supplements for Kidney Health
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share